204 related articles for article (PubMed ID: 16116145)
1. Lower phenytoin serum levels in persons switched from brand to generic phenytoin.
Jefferys RJ
Neurology; 2005 Aug; 65(4):657-8; author reply 657-8. PubMed ID: 16116145
[No Abstract] [Full Text] [Related]
2. Lower phenytoin serum levels in persons switched from brand to generic phenytoin.
Perron R
Neurology; 2005 Apr; 64(8):1485-6; author reply 1485-6; discussion 1485-6. PubMed ID: 15858865
[No Abstract] [Full Text] [Related]
3. Lower phenytoin serum levels in persons switched from brand to generic phenytoin.
Stetz SA
Neurology; 2005 Aug; 65(4):657-8; author reply 657-8. PubMed ID: 16118861
[No Abstract] [Full Text] [Related]
4. Lower phenytoin serum levels in persons switched from brand to generic phenytoin.
Rackley RJ
Neurology; 2005 Aug; 65(4):657-8; author reply 657-8. PubMed ID: 16118860
[No Abstract] [Full Text] [Related]
5. Lower phenytoin serum levels in persons switched from brand to generic phenytoin.
Sherry JH; Bechtel T
Neurology; 2005 Aug; 65(4):657-8; author reply 657-8. PubMed ID: 16118859
[No Abstract] [Full Text] [Related]
6. Lower phenytoin serum levels in persons switched from brand to generic phenytoin.
Wiberg CC
Neurology; 2005 Apr; 64(8):1485-6; author reply 1485-6; discussion 1485-6. PubMed ID: 15851759
[No Abstract] [Full Text] [Related]
7. Lower phenytoin serum levels in persons switched from brand to generic phenytoin.
Burkhardt RT; Leppik IE; Blesi K; Scott S; Gapany SR; Cloyd JC
Neurology; 2004 Oct; 63(8):1494-6. PubMed ID: 15505173
[TBL] [Abstract][Full Text] [Related]
8. Conflicts of interest with the health industry.
Dubois MY
Pain Med; 2006; 7(5):463-5. PubMed ID: 17014609
[No Abstract] [Full Text] [Related]
9. Unravelling industry bias in clinical trials.
Gluud LL
Pain; 2006 Apr; 121(3):175-176. PubMed ID: 16513277
[No Abstract] [Full Text] [Related]
10. Financial disclosure for review authors.
Nat Neurosci; 2003 Oct; 6(10):997. PubMed ID: 14513027
[No Abstract] [Full Text] [Related]
11. Psychotropic effects of antiepileptic drugs.
Boylan LS
Neurology; 2007 Oct; 69(16):1640; author reply 1640. PubMed ID: 17938375
[No Abstract] [Full Text] [Related]
12. Editorial policies on financial disclosure.
Carroll BJ; Rubin RT
Nat Neurosci; 2003 Oct; 6(10):999-1000; author reply 1000-1. PubMed ID: 14513028
[No Abstract] [Full Text] [Related]
13. Comparison of levetiracetam and controlled-release carbamazepine in newly diagnosed epilepsy.
Sethi NK; Torgovnick J; Arsura E
Neurology; 2007 Aug; 69(9):937; author reply 937-8. PubMed ID: 17724302
[No Abstract] [Full Text] [Related]
14. Editorial policies on financial disclosure.
Jacobson MF; Sharpe VA; Angell M; Ashford NA; Blum A; Chary LK; Cho M; Coull BC; Davis D; Doolittle RF; Egilman D; Epstein SS; Greenberg M; Hooper K; Huff J; Joshi TK; Krimsky S; LaDou J; Levenstein C; Miles S; Needleman H; Pellegrino ED; Ravanesi B; Sass J; Schecter A; Schneiderman JS; Schubert D; Soffritti M; Suzuki D; Takaro TK; Temple NJ; Terracini B; Thompson A; Wallinga D; Wing S
Nat Neurosci; 2003 Oct; 6(10):1001. PubMed ID: 14513030
[No Abstract] [Full Text] [Related]
15. Notice of failure to disclose financial interest: "A neuropsychological test battery for use in Alzheimer disease clinical trials" (Arch Neurol. 2007;64[9]:1323-1329).
Harrison J
Arch Neurol; 2008 Jul; 65(7):992. PubMed ID: 18625878
[No Abstract] [Full Text] [Related]
16. Out in the open.
Nat Biotechnol; 2005 Feb; 23(2):153. PubMed ID: 15696130
[No Abstract] [Full Text] [Related]
17. Estimation of population pharmacokinetic parameters of free-phenytoin in adult epileptic patients.
Deleu D; Aarons L; Ahmed IA
Arch Med Res; 2005; 36(1):49-53. PubMed ID: 15777995
[TBL] [Abstract][Full Text] [Related]
18. Generic substitution in the treatment of epilepsy: case evidence of breakthrough seizures.
Berg MJ; Gross RA; Tomaszewski KJ; Zingaro WM; Haskins LS
Neurology; 2008 Aug; 71(7):525-30. PubMed ID: 18695164
[TBL] [Abstract][Full Text] [Related]
19. Dilantin jeopardy: avoiding the dangers of phenytoin.
Schlicher ML
Medsurg Nurs; 1998 Dec; 7(6):343-7, 356. PubMed ID: 10036438
[TBL] [Abstract][Full Text] [Related]
20. Is bioavailability altered in generic versus brand anticonvulsants?
Jankovic SM; Ignjatovic Ristic D
Expert Opin Drug Metab Toxicol; 2015 Mar; 11(3):329-32. PubMed ID: 25440299
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
